We therefore suggest that targeting of the CoREST complex in melanoma may provide a successful therapeutic approach to inhibit cellular plasticity and therapeutic resistance in human melanomas, while promoting antitumor immunity, which should be broadly applicable to other cancers that undergo similar epigenetic reprogramming. This evidence concerns the gene RCOR1 and melanoma.